fedratinib: mpn-associated myelofibrosis
Published 4 years ago • 81 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
2:07
fedratinib for myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:03
preliminary results of a phase ii study of fedratinib in patients with mds/mpn and cnl
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
14:40
primary myelofibrosis (pmf)
-
5:10
what are the treatment options for myelofibrosis?
-
14:38
hematology in 10 min hemostasis and coagulation mp4 final
-
1:27
real-world use of fedratinib in patients with mf who have failed on ruxolitinib
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
1:01
latest advances in myelofibrosis treatment
-
1:52
maic of momelotinib versus fedratinib safety in myelofibrosis
-
2:33
spleen volume responses in fedratinib treated myelofibrosis patients
-
5:24
krt‑232: first-in-class mdm2i for myelofibrosis r/r to jak inhibitor therapy
-
1:15
exploring the evolving treatment landscape of myelofibrosis
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
1:19
fedratibib improves hrqol in myelofribrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
2:00
the role of fedratinib in 2024 and beyond
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct